Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0.5% while targeting non-GAAP operating margin in upper half of 10% to 12% range

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.